Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR Mutation (CLTBME)

Sun Yat-sen University

Status: Not yet enrolling

Conditions: Brain Metastases

Treatments: Other: before or after target therapy; Other: Surgery or Radiotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT05616377

EGFR+BM

Details and patient eligibility

About

The goal of this observational study is to learn about the survival benefit of local therapy combination with target therapy in lung cancer brain metastases with EGFR mutation. The main questions it aims to answer are:

• Is local therapy performed before or after target therapy would provide survival benefit ?
• What kind of local therapy combining with target therapy would provide survival benefit, neurosurgical resection or radiotherapy?

Enrollment: 2,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Evidence of pathological diagnosis of primary tumor.
2. Brain metastases confirmed by enhanced magnetic resonance imaging.
3. Gene test indicated that EGFR mutation.
4. Complete clinical information.

Exclusion criteria

1. If surgical treatment is accepted, the surgical treatment is not tumor resection, but ventricle puncture, biopsy and other non-tumor reducing surgery.
2. Patients with 2 or more types of tumors.
3. Incomplete clinical information.

Trial design

2,000 participants in 2 patient groups

target therapy + local therapy group vs target therapy alone group

Treatment:

Other: Surgery or Radiotherapy

local therapy before target therapy group vs local therapy after target therapy group

Treatment:

Other: before or after target therapy